FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study

Liestal, Switzerland, 31 July 2025: Curatis Holding AG (SIX: CURN) announces that the US FDA has confirmed a Type B meeting to discuss the design of the pivotal Phase 3 study for corticorelin (C-PTBE-01) in peritumoral brain edema (PTBE).

The meeting is scheduled for 9 September 2025.